On 11 October 2026, DSBJ (002384.SZ) passed the HKEX Main Board listing hearing, with UBS, Haitong International, GF Securities and CITIC Securities as joint sponsors, ranking third globally in PCBs by 2025 revenue.
On 11 October 2026, HAICHANG HLDG (02255.HK) said controlling shareholder Yu Faxiang was placed under CSRC investigation on 9 October over suspected personal information disclosure violations, and the probe is unrelated to the Group.
On 11 October 2026, HANSOH PHARMA (03692.HK) said it refiled an EU marketing application for almonertinib (Aumseqa®) with the EMA on 29 September, and the EMA confirmed acceptance on 7 October, starting centralised review.
On 11 October 2026, LDROBOT (01236.HK) said it signed a pact with Huazhong University of Science and Technology on flexible 3D tactile sensing for embodied robots, covering sensor components and array systems with validation on dexterous hands and robotic arms.
On 30 September 2026, the CSRC disclosed its filing notice (dated 24 August 2026) allowing Amlogic (688099.SH) to issue up to 53,815,500 shares on the SEHK.
NewTimeSpace Research Institute data show that in the Q3 2026 ranking of HK IPO underwriters by service scale, 84 institutions together served about HK$1.4 trillion, with a markedly top-heavy profile. CICC HK led with HK$106.966 billion, closely followed by Goldman Sachs Asia (HK$105.051 bn) and HSBC (HK$104.878 bn), while GF (HK) (HK$98.228 bn) and Haitong Int'l (HK$81.843 bn) ranked fourth and fifth. Futu Securities took 13th with HK$49.187 bn, as internet brokers kept penetrating. Tail-end firms mostly served under HK$1 bn, more than 100 times below the leaders — a stark divide.
Hong Kong recent listings diverged this week, with BAIGE DIGITAL up 27.36%; CHINA SANDI down 45.83%; Z.AI led turnover at HK$2.089 billion; REFIRE slid 96.89%.
NewTimeSpace Research Institute data show 83 institutions acted as bookrunners for HK IPOs in Q3 2026. Futu Securities (HK) led with 18 deals, CLSA came second with 11, Tiger Brokers (HK) third with 10, Huatai and CICC HK tied fourth with 8 each, CMB International 7, and Haitong Int'l, GF (HK), ABCI Capital and CMBC 6 each. The 22 firms with 4+ mandates accounted for the bulk of bookrunner deals, while the 36 tail-end firms served just one each, a stark divide.
NewTimeSpace Research Institute data show 92 institutions provided HK IPO legal services in Q3 2026. King & Wood Mallesons led with 11 mandates, Jingtian & Gongcheng took 7, and Latham & Watkins, Commerce & Finance, Zhong Lun, Davis Polk, Haiwen and Hogan Lovells 5 each. Eight firms served 5+, 32 served 2+; the 60 tail-end firms just one each. PRC firms led on deal count; international firms still held a place in large, complex deals.
NewTimeSpace Research Institute data show 9 audit firms served Hong Kong IPOs in Q3 2026, with a markedly top-heavy profile. Ernst & Young (EY) led with 13 mandates, Deloitte Touche Tohmatsu ranked second with 6 and KPMG third with 4; Rongcheng (HK) and SHINEWING (HK) tied fourth with 2 each; Tianjian International, PricewaterhouseCoopers, BDO and Grant Thornton (HK) took 1 apiece. EY's lead was clear, and rankings within the Big Four diverged, with PwC serving just one mandate this quarter.
NewTimeSpace Research Institute data show 33 institutions sponsored Hong Kong IPOs in Q3 2026. CITIC Securities (HK) and CLSA tied first with 9 mandates each, CICC HK ranked third with 8, and Huatai, Haitong Int'l Capital and Goldman Sachs Asia tied fourth with 4 each. Six institutions served four or more mandates; three served 3, seven served 2 and 17 served just one, a stark tail. Chinese brokers stayed ahead in sponsorship, while foreign banks ranked lower overall.
NewTimeSpace Research Institute data show 84 institutions underwrote HK IPOs in Q3 2026. Futu Securities (HK) led with 20 mandates, ahead of CLSA and Tiger Brokers (HK) at 11 each, CICC HK and Huatai at 8, CMB International at 7, and GF (HK), Haitong Int'l, ABCI and CMBC at 6 each. The 21 firms with 4+ mandates took most deals, while 48 tail-end firms served just one each; internet brokers and Chinese houses led.
On 9 October 2026, JUJIANG CONS (01459.HK) applied to the CSRC to convert 400,000,000 Domestic Shares into H Shares, which would leave none in issue.
On 9 October 2026, Microintelligence passed the HKEX listing hearing, with Orient Securities International as sole sponsor; 2025 revenue was RMB 795.5 million.
On 9 Oct 2026, CIRC (01763.HK) said its subsidiary obtained NMPA drug registration for a 50mg 13C-urea breath test kit; launch expected in December 2026.
On 9 Oct 2026, HAIZHI TECH GP (02706.HK) signed a strategic cooperation framework deal with Jointown on pharma distribution digital transformation.
